Overview

A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A randomized, double-blind study to assess the safety and efficacy of EDP-305 in subjects with liver-biopsy proven Non-Alcoholic Steatohepatitis (NASH)
Phase:
Phase 2
Details
Lead Sponsor:
Enanta Pharmaceuticals